Aldeyra Therapeutics (Aldeyra Therapeutics) Total Liabilities : $28.53 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics Total Liabilities?

Aldeyra Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $28.53 Mil.

Aldeyra Therapeutics's quarterly Total Liabilities declined from Jun. 2023 ($25.73 Mil) to Sep. 2023 ($24.28 Mil) but then increased from Sep. 2023 ($24.28 Mil) to Dec. 2023 ($28.53 Mil).

Aldeyra Therapeutics's annual Total Liabilities increased from Dec. 2021 ($27.40 Mil) to Dec. 2022 ($30.28 Mil) but then declined from Dec. 2022 ($30.28 Mil) to Dec. 2023 ($28.53 Mil).

Aldeyra Therapeutics Total Liabilities Historical Data

The historical data trend for Aldeyra Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Total Liabilities Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

27.44

23.84

27.40

30.28

28.53

Aldeyra Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															30.28	30.98	25.73	24.28	28.53

Aldeyra Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aldeyra Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	22.26	+	(0.272	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	6	+	0)
	=	28.53

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	148.327	-	119.795
	=	28.53

Aldeyra Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	22.26	+	(0.272	+	-1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	6	+	0)
	=	28.53

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	148.327	-	119.795
	=	28.53

Aldeyra Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

137:Germany 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce	director	1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg	officer: See Remarks	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha	officer: Chief Development Officer	131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin	officer: SVP Corp. Dev. & Strategy	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu	director, 10 percent owner
Stephen J Tulipano	officer: Chief Financial Officer	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140